GAL and cancer: Many GPRs in the galectin (GAL) subfamily were associated with immune suppression and regulated cytotoxicity T cell fate (Cagnoni et al. 2021; Yang et al. 2021), highlighting potential therapeutic targets for cancer immunotherapy.